CAC
APGN

Cowen and Company’s Apexigen, Inc. Common Stock APGN Stock Holding History

Cowen and Company’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-300,000
Closed -$3.05M – 807
2022
Q2 		$3.05M Buy
+300,000
New +$3.04M 0.29% 51

Other funds holding APGN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cowen and Company's APGN Position: Q3 2022 in Review

Cowen and Company sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2022, closing a stake of 300,000 shares — an estimated $3.05M sold.

Cowen and Company first reported a position in APGN in Q2 2022 and held it in 1 quarter. The position peaked at $3.05M in Q2 2022. 18 funds tracked by Wall St. Rank hold APGN as of Q3 2022.

  • Cowen and Company reported no remaining Apexigen, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Cowen and Company sold 300,000 Apexigen, Inc. Common Stock shares in Q3 2022, an estimated $3.05M.
  • Cowen and Company first reported a position in Apexigen, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Cowen and Company's Apexigen, Inc. Common Stock position peaked at $3.05M in Q2 2022.
  • 18 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2022.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.